COST-EFFECTIVENESS ANALYSIS OF HISTAMINE DIHYDROCHLORIDE plus LOW DOSE INTERLEUKIN-2 VS STANDARD OF CARE FOR ACUTE MYELOID LEUKEMIA PATIENTS IN THEIR FIRST COMPLETE REMISSION: A UK PERSPECTIVE

被引：1
|
作者：
Magar, R. S. [1 ]
Purdy, C. [2 ]
Hayward, A. [2 ]
Einarson, T. R. [3 ]
Burnett, A. K. [4 ]
机构：
[1] AHRM Inc, Raleigh, NC USA
[2] AHRM Inc, Buffalo, NY USA
[3] Univ Toronto, Toronto, ON, Canada
[4] Cardiff Univ, Cardiff CF4 4XN, S Glam, Wales
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74334-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：A272 / A272
页数：1
相关论文
共 50 条
  • [31] LOW-DOSE INTERLEUKIN-2 FOLLOWING INTENSIFICATION THERAPY WITH HIGH-DOSE ARA-C FOR ACUTE MYELOGENOUS LEUKEMIA IN 1ST COMPLETE REMISSION
    STONE, R
    MURRAY, C
    BERG, D
    MAYER, R
    RITZ, J
    SOIFFER, R
    BLOOD, 1994, 84 (10) : A302 - A302
  • [32] Phase III study of immunotherapy with recombinant interleukin-2 (IL-2) versus no further therapy in acute myeloid leukemia (AML) patients ≥ 60 years in first complete remission (CALGB 9720).
    Baer, Maria R.
    George, Stephen L.
    Caligiuri, Michael A.
    Sanford, Ben L.
    O'Loughlin, Kieran L.
    Mrozek, Krysztof
    Kolitz, Jonathan E.
    Powell, Bayard L.
    Moore, Joseph O.
    Stone, Richard M.
    Bloomfield, Clara D.
    Larson, Richard A.
    BLOOD, 2006, 108 (11) : 129A - 129A
  • [33] Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
    Reed, SD
    Anstrom, KJ
    Ludmer, JA
    Glendenning, GA
    Schulman, KA
    CANCER, 2004, 101 (11) : 2574 - 2583
  • [34] COST-EFFECTIVENESS OF GEMTUZUMAB OZOGAMICIN IN COMBINATION WITH STANDARD CHEMOTHERAPY IN FIRST-LINE TREATMENT IN PATIENTS WITH CD-33-POSITIVE ACUTE MYELOID LEUKEMIA IN SPAIN
    Montesinos, P.
    Font, P.
    Mareque, M.
    Soto, J.
    Sierra, J.
    De La Fuente, A.
    Iglesias, T.
    Pulido, S.
    Llinares, J.
    Brockbank, J.
    Oyaguez, I
    Guinea, J. M.
    HAEMATOLOGICA, 2020, 105 : 204 - 205
  • [35] COST-EFFECTIVENESS OF BLINATUMOMAB VERSUS CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST HEMATOLOGICAL COMPLETE REMISSION WITH MINIMAL RESIDUAL DISEASE USING A MARKOV COHORT APPROACH
    Delea, T. E.
    Despiegel, N.
    Boyko, D.
    Dirnberger, F.
    Tiwana, S.
    Sapra, S.
    VALUE IN HEALTH, 2020, 23 : S36 - S37
  • [36] Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital
    Chan, Thomas S. Y.
    Marcella, Stephen W.
    Gill, Harinder
    Hwang, Yu-Yan
    Kwong, Yok-Lam
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (01) : 77 - 83
  • [37] Daily low dose interleukin 2 (IL-2) therapy with or without intermediate dose pulsing in acute myeloid leukemia (AML) patients (PTS) >60 years old in first complete remission (CR1):: A feasibility study (CALGB 9420).
    Caligiuri, MA
    Lee, EJ
    Baer, MR
    Dodge, R
    Cooke, K
    Szatrowski, T
    Schiffer, CA
    Bloomfield, CD
    Larson, RA
    BLOOD, 1999, 94 (10) : 76A - 76A
  • [38] Prolonged administration of low-dose interleukin-2 (IL-2) to patients (PTS) with acute myeloid leukemia (AML) in remission (CR) expands natural killer (NK) cells without significant clinical toxicity.
    Baer, MR
    Pixley, LA
    Schriber, JR
    Frankel, SR
    Fehniger, TA
    Herzig, GP
    Caligiuri, MA
    BLOOD, 1998, 92 (10) : 614A - 615A
  • [39] Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
    Galtier, Jean
    Alric, Camille
    Berard, Emilie
    Leguay, Thibaut
    Tavitian, Suzanne
    Bidet, Audrey
    Delabesse, Eric
    Rieu, Jean Baptiste
    Vial, Jean-Philippe
    Vergez, Francois
    Lechevalier, Nicolas
    Luquet, Isabelle
    Klein, Emilie
    de Grande, Anne-Charlotte
    Sarry, Audrey
    Pigneux, Arnaud
    Recher, Christian
    Bertoli, Sarah
    Dumas, Pierre-Yves
    BLOOD CANCER JOURNAL, 2021, 11 (11)
  • [40] Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
    Jean Galtier
    Camille Alric
    Emilie Bérard
    Thibaut Leguay
    Suzanne Tavitian
    Audrey Bidet
    Eric Delabesse
    Jean Baptiste Rieu
    Jean-Philippe Vial
    François Vergez
    Nicolas Lechevalier
    Isabelle Luquet
    Emilie Klein
    Anne-Charlotte de Grande
    Audrey Sarry
    Arnaud Pigneux
    Christian Récher
    Sarah Bertoli
    Pierre-Yves Dumas
    Blood Cancer Journal, 11
12345